Previous 10 | Next 10 |
2023-11-10 09:06:08 ET More on Pacira BioSciences Pacira BioSciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Pacira BioSciences, Inc. (PCRX) Q3 2023 Earnings Call Transcript Pacira BioSciences: Preparing For A Pivotal Q3 Earnings Pacira BioScienc...
— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will...
TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 14 th at 11:00AM...
2023-11-02 15:00:05 ET Pacira BioSciences, Inc. (PCRX) Q3 2023 Earnings Conference Call November 02, 2023 08:30 AM ET Company Participants Susan Mesco - Head of Investor Relations Dave Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financ...
2023-11-02 08:04:22 ET More on Pacira BioSciences Pacira BioSciences: Preparing For A Pivotal Q3 Earnings Pacira BioSciences: Sell-Off On Pain Relief Specialist - But Recovery Not Guaranteed Pacira BioSciences: Economic Returns Languish Required Growth Rates ...
-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWS...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Pacira BioSciences Inc. (PCRX) is expected to report $0.65 for Q3 2023
2023-11-02 06:15:00 ET Summary Pacira BioSciences is facing challenges that have impacted their growth trajectory, resulting in the stock hitting 52-week lows. The company offers innovative solutions for non-opioid pain management and regenerative health. The upcoming Q3 earni...
2023-11-01 12:55:04 ET More on Pacira BioSciences Pacira BioSciences: Sell-Off On Pain Relief Specialist - But Recovery Not Guaranteed Pacira BioSciences: Economic Returns Languish Required Growth Rates Pacira BioSciences CEO David Stack to step down TD Cowen...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
2024-07-02 14:00:06 ET Oren Livnat from H.C. Wainwright issued a price target of $57.00 for PCRX on 2024-07-02 12:36:00. The adjusted price target was set to $57.00. At the time of the announcement, PCRX was trading at $21.91. The overall price target consensus is at $48...